Seattle Genetics, Takeda's cancer drug meets main goal in trial

Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body.

http://ift.tt/1rycwWi